SNTI MEXC RealStocks
Own real SNTI shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-13 21:27:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Senti Biosciences Holdings, Inc. (SNTI) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0.14, with a market capitalization of $5.65M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.14 to $2.88. This page covers its latest market performance, valuation, price trends and company information.
$5.65M | |
$0.15 | |
$0.16 | |
$0.14 | |
$0.15 | |
73.06K | |
3.61M | |
-- | |
$2.88 | |
$0.14 | |
-- | |
-- |
Senti Biosciences Holdings, Inc. (SNTI) is trading at $0.14 in after-hours trading as of 2026-11-13 21:21:00, unchanged from the regular-session close of $0.14.
After-hours trading shows how investors are pricing SNTI after the regular session closes. The current after-hours price is near the regular-session close, indicating neutral after-hours sentiment.
Over the past seven days, Senti Biosciences Holdings, Inc. (SNTI) moved from $0.18 to $0.14, representing a decline of 19.03% ($0.03).
The stock traded between $0.14 and $0.18 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 261.95 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.2%
SNTI is currently trading at $0.14, placing it 0.2% of the way from its 52-week low of $0.14 to its 52-week high of $2.88. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 39 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Senti Biosciences Holdings, Inc. (SNTI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to SNTI, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between SNTI shares and USD.
SNTI Shares to USD
1.00 SNTI shares = 0.143 USD
Calculations are estimates based on the latest available price and are for reference only.